A Phase 3 interventional study of Gemigliptin and Placebo to Linagliptin in Type 2 DM Patients With Moderate or Severe Renal Impairment, sponsored by LG Life Sciences. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-03-23.
Sponsored by LG Life Sciences (part of LG Chem) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Renal Insufficiency with a site in Korea, Republic of — 4 open to participants now, 5 under way, none of them phase 3. Renal Insufficiency · Korea, Republic of.
Among the 35 studies in Renal Insufficiency with a site in Korea, Republic of, this one is the 17th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2013, is one of 9 in phase 3, and was the 17th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →4 of the 35 studies in Renal Insufficiency with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Jin Joo Park · Sites in Korea, Republic of
Ages 20+
Yonsei University · Sites in Korea, Republic of
Ages 19–85
The University of Queensland · Sites in Korea, Republic of, Australia, New Zealand and 2 more countries
Ages 18+
Medtronic · Sites in Korea, Republic of, United States, Argentina and 38 more countries
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 19 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 132 is above the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 209 across the 29 interventional studies, 5,000 across the 5 observational. Of the 28 that completed or were terminated, 11 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 35 have an industry lead sponsor. The 10 most frequent:
This study is registered under LG Life Sciences, one of the names counted as LG Chem. Under that name alone:
LG Life Sciences is the lead sponsor of 78 studies on the registry; none are open to participants now.
LG Chem has 1 study filed under Renal Insufficiency — fewer than ten, so there is no comparison to draw.
1 of the studies in Renal Insufficiency with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07550790Jin Joo ParkContrast-Induced Acute Kidney Injury Prevention in Acute Heart Failure | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Renal Insufficiency with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Therapuetic options are limited for Type 2 Diabetes Mellitus (T2DM) pateints with renal impairment. This clinical study is to asses safety and efficacy of the DPP-4 inhibitor gemigliptin in patients with type 2 DM and moderate or severe renal impairment for long-term peirod (52 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant will remain gemigliptin 50mg throughout entire study (52 weeks).
Drug: Gemigliptin
Participant who is randomized to placebo will be switched to linagliptin after 12 week and administered linagliptin by week 52.
Drug: Placebo to Linagliptin
HbA1c change
Time frame: HbA1c change from baseline to week 12
HbA1c Change
Time frame: HbA1c change from baselint to week 6, 52
FPG
Time frame: FPG change from baseline to week 6,12,52
Glycated albumin
Time frame: Glycated albumin change from baseline to week 6,12,52
Fructosamin
Time frame: Fructosamin change from baseline to week 6,12,52
Waist
Time frame: Waist change from baseline to week 12,52
HbA1c responser (HbA1c<7.0%)
Time frame: HbA1c responser rate at week 12,52
Fasting serum C-peptide
Time frame: Fasting serum C-peptide change from baseline to week 12,52
Fasting Lipid parameters
Time frame: Fasting Lipid parameters change from baseline to week 12,52
Albuminuria
Time frame: Albuminuria change from baseline to week 12,52
The record gives a start of Oct 2013, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gemigliptin